Gerresheimer’s Creditor Truce Buys a Window to Sell Centor and Restore Trust

Gerresheimer secures creditor lifeline, sells US unit Centor, and faces a critical June 2026 audit deadline amid accounting scandals and high volatility.

The German pharmaceutical packaging group Gerresheimer is navigating a multi-front crisis that has hammered its stock and forced a fire sale of a key US subsidiary. While the shares have clawed back roughly 54% from their February low of €15.57, they still trade near €24—more than 60% below the 52-week peak. The annualized volatility of around 95% underscores just how jittery the market remains.

A Creditor Lifeline with Strings Attached

In mid-April, Gerresheimer secured a critical reprieve from its lenders. An overwhelming 96% of Schuldschein holders—representing the full €870 million in outstanding notes—agreed to push back the deadline for submitting audited financial statements to September 2026. The move effectively postpones the maturity of the debt and suspends key leverage covenants until the fourth quarter. Without this breathing room, the company would have faced an immediate refinancing crunch.

The crisis traces back to accounting irregularities involving so-called bill-and-hold arrangements, where revenue was improperly booked in violation of IFRS rules. The 2024 revenue had to be corrected by €35 million, and adjusted operating profit by €24 million. Beyond that, Germany’s financial watchdog BaFin is investigating misstatements related to leasing liabilities of €65.5 million and improperly capitalized development costs. Impairment tests have already flagged non-cash writedowns of €220 million to €240 million, mainly tied to technology projects at Sensile Medical AG and the moulded-glass plant in Chicago.

Centor Sale Takes Center Stage

To shore up its balance sheet, Gerresheimer is pushing ahead with the sale of its US subsidiary Centor Inc., which specializes in packaging systems for prescription drugs. Morgan Stanley has been mandated to run the process, and the company reports a double-digit number of interested parties—a promising start. Management expects to close the deal before year-end, though it has not disclosed a target price.

The proceeds from the Centor divestiture are intended to strengthen the capital structure and provide a buffer against further financial strain. If successful, the sale could reduce the uncertainty discount that has weighed heavily on the stock.

A June Deadline That Could Make or Break the Rally

The audited annual report for fiscal 2025 is due in June 2026, with the first-quarter 2026 results to follow shortly after. That date looms large: a clean audit without further surprises would be the foundation for any sustained recovery. The shares have already rallied 24% in the past 30 days, but that gain rests on shaky ground until the books are certified.

Operationally, Gerresheimer is holding the line. For 2026, management targets revenue of €2.3 billion to €2.4 billion, an adjusted EBITDA margin of 18% to 19%, and moderately positive free cash flow. The Chicago Heights plant will close by year-end, with production shifting to facilities in Italy and India.

The company’s ejection from the SDAX index in April added to the pressure, but the creditor truce has at least bought time. Whether that time is used wisely—to complete the Centor sale and deliver a clean audit—will determine if the recent share price recovery is a genuine turnaround or just a temporary reprieve.